Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer

To investigate the usefulness of the overexpression of the human epidermal growth factor receptor (HER-2) oncoprotein in patients with bone metastatic prostate cancer as a marker for the time to recurrence and outcome after endocrine therapy. We studied 50 patients who had been diagnosed with bone m...

Full description

Saved in:

Bibliographic Details
Published in:	Urology (Ridgewood, N.J.) Vol. 68; no. 1; pp. 110 - 115
Main Authors:	Nishio, Yoshitaka, Yamada, Yoshiaki, Kokubo, Hiroto, Nakamura, Kogenta, Aoki, Shigeyuki, Taki, Tomohiro, Honda, Nobuaki, Nakagawa, Atsuko, Saga, Shinsuke, Hara, Kazuo
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01-07-2006 Elsevier Science
Subjects:	Aged Aged, 80 and over Biological and medical sciences Bone Neoplasms - secondary Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Male Male genital diseases Medical sciences Middle Aged Nephrology. Urinary tract diseases Prognosis Prostate - metabolism Prostatic Neoplasms - metabolism Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Receptor, ErbB-2 - metabolism Survival Rate Tumors Tumors of the urinary system Urinary tract. Prostate gland Immunohistochemistry Nephrology Urinary system disease Prognosis Prostate disease erbB2 Gene Malignant tumor Metastasis Urology Osteoarticular system Anatomic pathology C-Onc gene Oncoprotein Advanced stage Metastatic Bone Onc gene Male genital diseases Prostate cancer Protooncogene
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	To investigate the usefulness of the overexpression of the human epidermal growth factor receptor (HER-2) oncoprotein in patients with bone metastatic prostate cancer as a marker for the time to recurrence and outcome after endocrine therapy. We studied 50 patients who had been diagnosed with bone metastatic prostate cancer. HER-2 overexpression in the prostatic tissue by biopsy was evaluated by immunohistochemistry using the Hercep test. The results were scored into four levels by two pathologists; scores greater than 1+ were considered positive. The HER-2 staining score was 0, 1+, 2+, 3+, and indeterminate in 28, 4, 11, 6, and 1 case, respectively. HER-2 was overexpressed (greater than 1+) in 21 patients (42%). The cause-specific survival and nonrecurrence rates were significantly lower in the HER-2-positive group than in the negative group ( P = 0.0084 and P = 0.0485, respectively). Furthermore, the cause-specific survival rate after recurrence was significantly greater in the HER-2-negative group than in the positive group ( P = 0.0247). We consider that HER-2 overexpression, as measured by immunohistochemistry, may be useful as a marker of an unfavorable prognosis by predicting the interval until relapse and outcome after endocrine therapy in patients with bone metastatic prostate cancer.
AbstractList	To investigate the usefulness of the overexpression of the human epidermal growth factor receptor (HER-2) oncoprotein in patients with bone metastatic prostate cancer as a marker for the time to recurrence and outcome after endocrine therapy. We studied 50 patients who had been diagnosed with bone metastatic prostate cancer. HER-2 overexpression in the prostatic tissue by biopsy was evaluated by immunohistochemistry using the Hercep test. The results were scored into four levels by two pathologists; scores greater than 1+ were considered positive. The HER-2 staining score was 0, 1+, 2+, 3+, and indeterminate in 28, 4, 11, 6, and 1 case, respectively. HER-2 was overexpressed (greater than 1+) in 21 patients (42%). The cause-specific survival and nonrecurrence rates were significantly lower in the HER-2-positive group than in the negative group (P = 0.0084 and P = 0.0485, respectively). Furthermore, the cause-specific survival rate after recurrence was significantly greater in the HER-2-negative group than in the positive group (P = 0.0247). We consider that HER-2 overexpression, as measured by immunohistochemistry, may be useful as a marker of an unfavorable prognosis by predicting the interval until relapse and outcome after endocrine therapy in patients with bone metastatic prostate cancer. To investigate the usefulness of the overexpression of the human epidermal growth factor receptor (HER-2) oncoprotein in patients with bone metastatic prostate cancer as a marker for the time to recurrence and outcome after endocrine therapy. We studied 50 patients who had been diagnosed with bone metastatic prostate cancer. HER-2 overexpression in the prostatic tissue by biopsy was evaluated by immunohistochemistry using the Hercep test. The results were scored into four levels by two pathologists; scores greater than 1+ were considered positive. The HER-2 staining score was 0, 1+, 2+, 3+, and indeterminate in 28, 4, 11, 6, and 1 case, respectively. HER-2 was overexpressed (greater than 1+) in 21 patients (42%). The cause-specific survival and nonrecurrence rates were significantly lower in the HER-2-positive group than in the negative group ( P = 0.0084 and P = 0.0485, respectively). Furthermore, the cause-specific survival rate after recurrence was significantly greater in the HER-2-negative group than in the positive group ( P = 0.0247). We consider that HER-2 overexpression, as measured by immunohistochemistry, may be useful as a marker of an unfavorable prognosis by predicting the interval until relapse and outcome after endocrine therapy in patients with bone metastatic prostate cancer. OBJECTIVESTo investigate the usefulness of the overexpression of the human epidermal growth factor receptor (HER-2) oncoprotein in patients with bone metastatic prostate cancer as a marker for the time to recurrence and outcome after endocrine therapy.METHODSWe studied 50 patients who had been diagnosed with bone metastatic prostate cancer. HER-2 overexpression in the prostatic tissue by biopsy was evaluated by immunohistochemistry using the Hercep test. The results were scored into four levels by two pathologists; scores greater than 1+ were considered positive.RESULTSThe HER-2 staining score was 0, 1+, 2+, 3+, and indeterminate in 28, 4, 11, 6, and 1 case, respectively. HER-2 was overexpressed (greater than 1+) in 21 patients (42%). The cause-specific survival and nonrecurrence rates were significantly lower in the HER-2-positive group than in the negative group (P = 0.0084 and P = 0.0485, respectively). Furthermore, the cause-specific survival rate after recurrence was significantly greater in the HER-2-negative group than in the positive group (P = 0.0247).CONCLUSIONSWe consider that HER-2 overexpression, as measured by immunohistochemistry, may be useful as a marker of an unfavorable prognosis by predicting the interval until relapse and outcome after endocrine therapy in patients with bone metastatic prostate cancer.
Author	Taki, Tomohiro Honda, Nobuaki Yamada, Yoshiaki Nakagawa, Atsuko Saga, Shinsuke Nishio, Yoshitaka Kokubo, Hiroto Nakamura, Kogenta Aoki, Shigeyuki Hara, Kazuo
Author_xml	– sequence: 1 givenname: Yoshitaka surname: Nishio fullname: Nishio, Yoshitaka organization: Department of Urology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 2 givenname: Yoshiaki surname: Yamada fullname: Yamada, Yoshiaki email: 101959@gk.amu.aichi-med-u.ac.jp organization: Department of Urology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 3 givenname: Hiroto surname: Kokubo fullname: Kokubo, Hiroto organization: Department of Urology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 4 givenname: Kogenta surname: Nakamura fullname: Nakamura, Kogenta organization: Department of Urology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 5 givenname: Shigeyuki surname: Aoki fullname: Aoki, Shigeyuki organization: Department of Urology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 6 givenname: Tomohiro surname: Taki fullname: Taki, Tomohiro organization: Department of Urology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 7 givenname: Nobuaki surname: Honda fullname: Honda, Nobuaki organization: Department of Urology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 8 givenname: Atsuko surname: Nakagawa fullname: Nakagawa, Atsuko organization: Department of Pathology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 9 givenname: Shinsuke surname: Saga fullname: Saga, Shinsuke organization: Department of Pathology, Aichi Medical University School of Medicine, Aichi, Japan – sequence: 10 givenname: Kazuo surname: Hara fullname: Hara, Kazuo organization: Division of Pathology, Aichi Medical University Hospital, Aichi, Japan
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17981347$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16806433$$D View this record in MEDLINE/PubMed
BookMark	eNqFkE1r3DAQhkVJaTYfP6FFl-ZmR7Il2T6VEtKkEGgp7VnI8mhXiy1tJTlk_33lriHHgECCeWbm1XOBzpx3gNBHSkpKqLjdl3Pwo98ey4oQURJaEkHeoQ3lVVN0XcfP0IaQjhSs6vg5uohxTzIoRPMBnVPREsHqeoOOP4PfOh-T1TjarbPGauU0YG-wnabZ-Z2NyesdTLkwYng5BIjRercQaQf48f5XUd06mLF32h-CT2AdzqfPgfEEScWklvG5tLwA_18QrtB7o8YI1-t9if58u_9991g8_Xj4fvf1qdCMd6kAShXnvOkbo6jQxAzcDEMvKGHN0NL8MqyGDgSvBtrWgmhRsbqirem5YgbqS3Rzmpv3_50hJjnZqGEclQM_RylawXhbNxnkJ1DnoDGAkYdgJxWOkhK5OJd7uTqXi3NJqMzOc9-ndcHcTzC8dq2SM_B5BVTMDk3I_7fxlWu6ltZsCfDlxEHW8WwhyKgtZFeDDaCTHLx9I8o_5x6nLg
CODEN	URGYAZ
CitedBy_id	crossref_primary_10_1517_17530059_2_6_691 crossref_primary_10_3390_onco3020008 crossref_primary_10_1016_j_anndiagpath_2023_152219 crossref_primary_10_3892_or_2012_2079 crossref_primary_10_1097_MED_0b013e3282f315ef crossref_primary_10_1016_j_bbcan_2012_02_002 crossref_primary_10_3892_etm_00000099 crossref_primary_10_3390_cancers5020569 crossref_primary_10_1158_1078_0432_CCR_07_0330 crossref_primary_10_1080_10611860802471562 crossref_primary_10_1111_j_1600_0463_2008_0s123_x crossref_primary_10_1158_0008_5472_CAN_09_0941 crossref_primary_10_1155_2015_285193 crossref_primary_10_1016_j_critrevonc_2011_02_005 crossref_primary_10_1038_aja_2008_38 crossref_primary_10_2353_ajpath_2010_100228 crossref_primary_10_1158_1541_7786_MCR_07_0211 crossref_primary_10_1074_jbc_M110_143792 crossref_primary_10_3390_cancers13030549 crossref_primary_10_1007_s42399_021_00861_z crossref_primary_10_1111_j_1745_7262_2008_00433_x crossref_primary_10_1016_j_urology_2009_01_018 crossref_primary_10_1002_pros_20747 crossref_primary_10_1016_j_ijbiomac_2019_07_085 crossref_primary_10_1097_CCO_0000000000000281 crossref_primary_10_1111_j_1442_2042_2009_02253_x
Cites_doi	10.1002/cncr.20228 10.3322/canjclin.39.1.3 10.1016/0046-8177(92)90108-F 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9 10.1093/jnci/92.23.1918 10.1016/S0959-8049(01)00350-1 10.1016/S0022-5347(17)35799-3 10.1002/pros.20065 10.1046/j.1365-2559.2001.01084.x 10.1200/JCO.1997.15.8.2894 10.1136/jcp.2003.007724 10.1016/S0959-8049(96)00492-3 10.1002/cncr.10339 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U 10.1126/science.2470152 10.1056/NEJM200103153441101 10.1200/JCO.1999.17.7.1974 10.1056/NEJMoa041318 10.1126/science.3798106 10.1056/NEJMoa040720 10.1073/pnas.89.10.4285 10.1016/j.urology.2005.01.026
ContentType	Journal Article
Copyright	2006 Elsevier Inc. 2006 INIST-CNRS
Copyright_xml	– notice: 2006 Elsevier Inc. – notice: 2006 INIST-CNRS
DBID	IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8
DOI	10.1016/j.urology.2006.01.060
DatabaseName	Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1527-9995
EndPage	115
ExternalDocumentID	10_1016_j_urology_2006_01_060 16806433 17981347 S0090429506001300
Genre	Journal Article
GroupedDBID	--- --K --M -RU .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAEJM AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFNM ABLJU ABLVK ABMAC ABMZM ABOCM ABXDB ABYKQ ACDAQ ACIUM ACRLP ACRZS ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJJEV AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HZ~ IHE J1W KOM L7B LCYCR LZ2 M29 M41 MO0 N9A O-L O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSH SSZ T5K UV1 WH7 WOW WUQ X7M XPP Z5R ZA5 ZGI ~G- 08R AAPBV AAUGY ABPIF ABPTK IQODW AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8
ID	FETCH-LOGICAL-c459t-e11a5557b7fa16c0fd5fddb61047d81db6f43e9e652d18360c6243218fb5a4fe3
ISSN	0090-4295
IngestDate	Sat Oct 26 00:14:24 EDT 2024 Thu Sep 26 15:52:53 EDT 2024 Sat Sep 28 07:42:54 EDT 2024 Sun Oct 22 16:06:29 EDT 2023 Fri Feb 23 02:11:22 EST 2024
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Immunohistochemistry Nephrology Urinary system disease Prognosis Prostate disease erbB2 Gene Malignant tumor Metastasis Urology Osteoarticular system Anatomic pathology C-Onc gene Oncoprotein Advanced stage Metastatic Bone Onc gene Male genital diseases Prostate cancer Protooncogene
Language	English
License	CC BY 4.0
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c459t-e11a5557b7fa16c0fd5fddb61047d81db6f43e9e652d18360c6243218fb5a4fe3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	16806433
PQID	68645837
PQPubID	23479
PageCount	6
ParticipantIDs	proquest_miscellaneous_68645837 crossref_primary_10_1016_j_urology_2006_01_060 pubmed_primary_16806433 pascalfrancis_primary_17981347 elsevier_sciencedirect_doi_10_1016_j_urology_2006_01_060
PublicationCentury	2000
PublicationDate	2006-07-01
PublicationDateYYYYMMDD	2006-07-01
PublicationDate_xml	– month: 07 year: 2006 text: 2006-07-01 day: 01
PublicationDecade	2000
PublicationPlace	New York, NY
PublicationPlace_xml	– name: New York, NY – name: United States
PublicationTitle	Urology (Ridgewood, N.J.)
PublicationTitleAlternate	Urology
PublicationYear	2006
Publisher	Elsevier Inc Elsevier Science
Publisher_xml	– name: Elsevier Inc – name: Elsevier Science
References	Ziada, Barqawi, Glode (bib27) 2004; 60 Kuhn, Kurnot, Sesterhenn (bib16) 1993; 150 Slamon, Clark, Wong (bib6) 1987; 235 Carter, Presta, Gorman (bib12) 1992; 89 Bray, Sankila, Ferlay (bib1) 2002; 38 Tannock, de Wit, Berry (bib23) 2004; 351 Ito, Kubota, Yamamoto (bib5) 2000; 13 (bib4) 1999 Signoretti, Montironi, Manola (bib18) 2000; 92 Gleason (bib10) 1992; 23 Slamon, Godolphin, Jones (bib7) 1989; 244 Mass, Sanders, Charlene (bib13) 2000; 19 Slamon, Leyland-Jones, Shak (bib25) 2001; 344 Silverberg, Lubera (bib3) 1989; 39 Morris, Reuter, Kelly (bib26) 2002; 94 Press, Bernstein, Thomas (bib8) 1997; 15 Sobin, Wittekind (bib11) 1997 Lara, Chee, Longmate (bib21) 2004; 100 Kokubo, Yamada, Nishio (bib22) 2005; 66 Jacobs, Gown, Yaziji (bib14) 1999; 17 Morote, de Torres, Caceres (bib17) 1999; 84 Ellis, Bartlett, Dowsett (bib9) 2004; 57 Ross, Sheehan, Hayner-Buchan (bib15) 1997; 79 Barrios, Caron, Leal (bib20) 2001; 20 Black, Bray, Ferlay (bib2) 1997; 33 Petrylak, Tangen, Hussain (bib24) 2004; 351 Koeppen, Wright, Burt (bib19) 2001; 38 Ellis (10.1016/j.urology.2006.01.060_bib9) 2004; 57 Mass (10.1016/j.urology.2006.01.060_bib13) 2000; 19 Signoretti (10.1016/j.urology.2006.01.060_bib18) 2000; 92 Press (10.1016/j.urology.2006.01.060_bib8) 1997; 15 Bray (10.1016/j.urology.2006.01.060_bib1) 2002; 38 Black (10.1016/j.urology.2006.01.060_bib2) 1997; 33 Silverberg (10.1016/j.urology.2006.01.060_bib3) 1989; 39 Gleason (10.1016/j.urology.2006.01.060_bib10) 1992; 23 Koeppen (10.1016/j.urology.2006.01.060_bib19) 2001; 38 Ziada (10.1016/j.urology.2006.01.060_bib27) 2004; 60 Kokubo (10.1016/j.urology.2006.01.060_bib22) 2005; 66 Jacobs (10.1016/j.urology.2006.01.060_bib14) 1999; 17 Morris (10.1016/j.urology.2006.01.060_bib26) 2002; 94 Ito (10.1016/j.urology.2006.01.060_bib5) 2000; 13 Slamon (10.1016/j.urology.2006.01.060_bib6) 1987; 235 Morote (10.1016/j.urology.2006.01.060_bib17) 1999; 84 Slamon (10.1016/j.urology.2006.01.060_bib25) 2001; 344 Lara (10.1016/j.urology.2006.01.060_bib21) 2004; 100 Barrios (10.1016/j.urology.2006.01.060_bib20) 2001; 20 Sobin (10.1016/j.urology.2006.01.060_bib11) 1997 (10.1016/j.urology.2006.01.060_bib4) 1999 Tannock (10.1016/j.urology.2006.01.060_bib23) 2004; 351 Carter (10.1016/j.urology.2006.01.060_bib12) 1992; 89 Kuhn (10.1016/j.urology.2006.01.060_bib16) 1993; 150 Slamon (10.1016/j.urology.2006.01.060_bib7) 1989; 244 Ross (10.1016/j.urology.2006.01.060_bib15) 1997; 79 Petrylak (10.1016/j.urology.2006.01.060_bib24) 2004; 351
References_xml	– volume: 38 start-page: 96 year: 2001 end-page: 104 ident: bib19 article-title: Overexpression of HER2/neu in solid tumors publication-title: Histopathology contributor: fullname: Burt – volume: 33 start-page: 1075 year: 1997 end-page: 1107 ident: bib2 article-title: Cancer incidence and mortality in the European Union publication-title: Eur J Cancer contributor: fullname: Ferlay – volume: 235 start-page: 177 year: 1987 end-page: 182 ident: bib6 article-title: Human breast cancer publication-title: Science contributor: fullname: Wong – volume: 344 start-page: 783 year: 2001 end-page: 792 ident: bib25 article-title: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 publication-title: N Engl J Med contributor: fullname: Shak – volume: 20 start-page: 2432 year: 2001 ident: bib20 article-title: HER2 expression in prostate cancer publication-title: Proc Am Soc Clin Oncol contributor: fullname: Leal – volume: 92 start-page: 1918 year: 2000 end-page: 1925 ident: bib18 article-title: HER-2-neu expression and progression toward androgen independence in human prostate cancer publication-title: J Natl Cancer Inst contributor: fullname: Manola – volume: 66 start-page: 135 year: 2005 end-page: 140 ident: bib22 article-title: Immunohistochemical study of chromogranin A in stage D2 prostate cancer publication-title: Urology contributor: fullname: Nishio – volume: 39 start-page: 3 year: 1989 end-page: 20 ident: bib3 article-title: Cancer statistics, 1989 publication-title: CA Cancer J Clin contributor: fullname: Lubera – year: 1997 ident: bib11 article-title: TNM Classification of Malignant Tumors contributor: fullname: Wittekind – year: 1999 ident: bib4 publication-title: Cancer Statistics in Japan 1999 – volume: 89 start-page: 4285 year: 1992 end-page: 4289 ident: bib12 article-title: Humanization of an anti-p185 publication-title: Proc Natl Acad Sci USA contributor: fullname: Gorman – volume: 351 start-page: 1502 year: 2004 end-page: 1512 ident: bib23 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer publication-title: N Engl J Med contributor: fullname: Berry – volume: 60 start-page: 332 year: 2004 end-page: 337 ident: bib27 article-title: The use of trastuzumab in the treatment of hormone refractory prostate cancer; Phase II trial publication-title: Prostate contributor: fullname: Glode – volume: 19 start-page: 291 year: 2000 ident: bib13 article-title: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials publication-title: Proc Am Soc Clin Oncol contributor: fullname: Charlene – volume: 13 start-page: 997 year: 2000 end-page: 1001 ident: bib5 article-title: The change of mass screening system for prostate cancer in Gunma Prefecture—present state, and problems for 18 years publication-title: Jpn J Urol Surg contributor: fullname: Yamamoto – volume: 15 start-page: 2894 year: 1997 end-page: 2904 ident: bib8 article-title: HER-2/neu gene amplification characterized by fluorescence in situ hybridization publication-title: J Clin Oncol contributor: fullname: Thomas – volume: 351 start-page: 1513 year: 2004 end-page: 1520 ident: bib24 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N Engl J Med contributor: fullname: Hussain – volume: 23 start-page: 273 year: 1992 end-page: 279 ident: bib10 article-title: Histologic grading of prostate cancer publication-title: Hum Pathol contributor: fullname: Gleason – volume: 244 start-page: 707 year: 1989 end-page: 712 ident: bib7 article-title: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer publication-title: Science contributor: fullname: Jones – volume: 100 start-page: 2125 year: 2004 end-page: 2131 ident: bib21 article-title: Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma publication-title: Cancer contributor: fullname: Longmate – volume: 94 start-page: 980 year: 2002 end-page: 986 ident: bib26 article-title: HER-2 profiling and targeting in prostate carcinoma publication-title: Cancer contributor: fullname: Kelly – volume: 79 start-page: 2162 year: 1997 end-page: 2170 ident: bib15 article-title: Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma publication-title: Cancer contributor: fullname: Hayner-Buchan – volume: 38 start-page: 99 year: 2002 end-page: 166 ident: bib1 article-title: Estimates of cancer incidence and mortality in Europe in 1995 publication-title: Eur J Cancer contributor: fullname: Ferlay – volume: 57 start-page: 233 year: 2004 end-page: 237 ident: bib9 article-title: Update recommendations for HER2 testing in the UK publication-title: J Clin Pathol contributor: fullname: Dowsett – volume: 150 start-page: 1427 year: 1993 end-page: 1433 ident: bib16 article-title: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma publication-title: J Urol contributor: fullname: Sesterhenn – volume: 84 start-page: 421 year: 1999 end-page: 425 ident: bib17 article-title: Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer publication-title: Int J Cancer contributor: fullname: Caceres – volume: 17 start-page: 1974 year: 1999 ident: bib14 article-title: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer publication-title: J Clin Oncol contributor: fullname: Yaziji – volume: 19 start-page: 291 year: 2000 ident: 10.1016/j.urology.2006.01.060_bib13 article-title: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials publication-title: Proc Am Soc Clin Oncol contributor: fullname: Mass – volume: 100 start-page: 2125 year: 2004 ident: 10.1016/j.urology.2006.01.060_bib21 article-title: Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma publication-title: Cancer doi: 10.1002/cncr.20228 contributor: fullname: Lara – volume: 39 start-page: 3 year: 1989 ident: 10.1016/j.urology.2006.01.060_bib3 article-title: Cancer statistics, 1989 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.39.1.3 contributor: fullname: Silverberg – volume: 23 start-page: 273 year: 1992 ident: 10.1016/j.urology.2006.01.060_bib10 article-title: Histologic grading of prostate cancer publication-title: Hum Pathol doi: 10.1016/0046-8177(92)90108-F contributor: fullname: Gleason – volume: 84 start-page: 421 year: 1999 ident: 10.1016/j.urology.2006.01.060_bib17 article-title: Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9 contributor: fullname: Morote – volume: 92 start-page: 1918 year: 2000 ident: 10.1016/j.urology.2006.01.060_bib18 article-title: HER-2-neu expression and progression toward androgen independence in human prostate cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.23.1918 contributor: fullname: Signoretti – volume: 38 start-page: 99 year: 2002 ident: 10.1016/j.urology.2006.01.060_bib1 article-title: Estimates of cancer incidence and mortality in Europe in 1995 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(01)00350-1 contributor: fullname: Bray – volume: 150 start-page: 1427 year: 1993 ident: 10.1016/j.urology.2006.01.060_bib16 article-title: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma publication-title: J Urol doi: 10.1016/S0022-5347(17)35799-3 contributor: fullname: Kuhn – volume: 60 start-page: 332 year: 2004 ident: 10.1016/j.urology.2006.01.060_bib27 article-title: The use of trastuzumab in the treatment of hormone refractory prostate cancer; Phase II trial publication-title: Prostate doi: 10.1002/pros.20065 contributor: fullname: Ziada – volume: 38 start-page: 96 year: 2001 ident: 10.1016/j.urology.2006.01.060_bib19 article-title: Overexpression of HER2/neu in solid tumors publication-title: Histopathology doi: 10.1046/j.1365-2559.2001.01084.x contributor: fullname: Koeppen – volume: 15 start-page: 2894 year: 1997 ident: 10.1016/j.urology.2006.01.060_bib8 article-title: HER-2/neu gene amplification characterized by fluorescence in situ hybridization publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.8.2894 contributor: fullname: Press – volume: 57 start-page: 233 year: 2004 ident: 10.1016/j.urology.2006.01.060_bib9 article-title: Update recommendations for HER2 testing in the UK publication-title: J Clin Pathol doi: 10.1136/jcp.2003.007724 contributor: fullname: Ellis – volume: 33 start-page: 1075 year: 1997 ident: 10.1016/j.urology.2006.01.060_bib2 article-title: Cancer incidence and mortality in the European Union publication-title: Eur J Cancer doi: 10.1016/S0959-8049(96)00492-3 contributor: fullname: Black – volume: 94 start-page: 980 year: 2002 ident: 10.1016/j.urology.2006.01.060_bib26 article-title: HER-2 profiling and targeting in prostate carcinoma publication-title: Cancer doi: 10.1002/cncr.10339 contributor: fullname: Morris – volume: 79 start-page: 2162 year: 1997 ident: 10.1016/j.urology.2006.01.060_bib15 article-title: Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U contributor: fullname: Ross – year: 1997 ident: 10.1016/j.urology.2006.01.060_bib11 contributor: fullname: Sobin – volume: 244 start-page: 707 year: 1989 ident: 10.1016/j.urology.2006.01.060_bib7 article-title: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer publication-title: Science doi: 10.1126/science.2470152 contributor: fullname: Slamon – volume: 13 start-page: 997 year: 2000 ident: 10.1016/j.urology.2006.01.060_bib5 article-title: The change of mass screening system for prostate cancer in Gunma Prefecture—present state, and problems for 18 years publication-title: Jpn J Urol Surg contributor: fullname: Ito – volume: 20 start-page: 2432 year: 2001 ident: 10.1016/j.urology.2006.01.060_bib20 article-title: HER2 expression in prostate cancer publication-title: Proc Am Soc Clin Oncol contributor: fullname: Barrios – volume: 344 start-page: 783 year: 2001 ident: 10.1016/j.urology.2006.01.060_bib25 article-title: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 publication-title: N Engl J Med doi: 10.1056/NEJM200103153441101 contributor: fullname: Slamon – volume: 17 start-page: 1974 year: 1999 ident: 10.1016/j.urology.2006.01.060_bib14 article-title: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.7.1974 contributor: fullname: Jacobs – volume: 351 start-page: 1513 year: 2004 ident: 10.1016/j.urology.2006.01.060_bib24 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa041318 contributor: fullname: Petrylak – year: 1999 ident: 10.1016/j.urology.2006.01.060_bib4 – volume: 235 start-page: 177 year: 1987 ident: 10.1016/j.urology.2006.01.060_bib6 article-title: Human breast cancer publication-title: Science doi: 10.1126/science.3798106 contributor: fullname: Slamon – volume: 351 start-page: 1502 year: 2004 ident: 10.1016/j.urology.2006.01.060_bib23 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa040720 contributor: fullname: Tannock – volume: 89 start-page: 4285 year: 1992 ident: 10.1016/j.urology.2006.01.060_bib12 article-title: Humanization of an anti-p185HER2 antibody for human cancer therapy publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.89.10.4285 contributor: fullname: Carter – volume: 66 start-page: 135 year: 2005 ident: 10.1016/j.urology.2006.01.060_bib22 article-title: Immunohistochemical study of chromogranin A in stage D2 prostate cancer publication-title: Urology doi: 10.1016/j.urology.2005.01.026 contributor: fullname: Kokubo
SSID	ssj0006667
Score	2.02764
Snippet	To investigate the usefulness of the overexpression of the human epidermal growth factor receptor (HER-2) oncoprotein in patients with bone metastatic prostate... OBJECTIVESTo investigate the usefulness of the overexpression of the human epidermal growth factor receptor (HER-2) oncoprotein in patients with bone...
SourceID	proquest crossref pubmed pascalfrancis elsevier
SourceType	Aggregation Database Index Database Publisher
StartPage	110
SubjectTerms	Aged Aged, 80 and over Biological and medical sciences Bone Neoplasms - secondary Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Male Male genital diseases Medical sciences Middle Aged Nephrology. Urinary tract diseases Prognosis Prostate - metabolism Prostatic Neoplasms - metabolism Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Receptor, ErbB-2 - metabolism Survival Rate Tumors Tumors of the urinary system Urinary tract. Prostate gland
Title	Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer
URI	https://dx.doi.org/10.1016/j.urology.2006.01.060 https://www.ncbi.nlm.nih.gov/pubmed/16806433 https://search.proquest.com/docview/68645837
Volume	68
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3ra9swEBdpC2Mwxp5d9uj0Yd-KU8sP2flYtoyssDDWFtpPRrIlaEuikMSw_fe7k-RHt5Q9YBCM40SW4vvl7nT63YmQd1GqwCwIFjDBoiBJwzLIRSyCLFFKS1Xp0O48Nz3NZhf5h0kyGQyaGq7dtf8qabgGssbM2b-QdntTuADnIHM4gtTh-Edy_7IyyJ3DOqzIzUAmkM0KwNIQmAtibIXhsqkToL55JuyiYQtMJ18DWy5V1YdmURpbyeHKEiKlAZd0rjYC05CggyWmjICzemi7WPUd3fOVK-6EEQpMCWuoPbPRyagXfZhhCMxGay8NnG3ETWsmLsVcVKL9CDzd1jiYm1raRtMrGJxpbwat5_XKJbkZmzP2c1Aj6wc12mybW2RQcAfDAOynWwVXXmFHWQBObtrX6Dz_BblOPTNPoVX-XbrViLh4xvWodk_Kr1ixUcjDzmq2XMZTHBaOKuR2GTjcIXsRaD1QunvHnyYXJ61jADNFX8LV_Ywuoexoa2d3uUoPlmINCNFu55W7p0bWRTp7RB76uQ09dqB8TAZq8YTc--zZG0_J9w6btI9NajTdgk3aYRO_AdikFptHgEzaQyaFFyKTdsikDTKpQ-Yzcv5xcvZ-GvitP4IyScebQDEm0jTNZKYF42Woq1RXleRYWKSCKZbkOonVWPE0qhjmIZU8SmJwV7VMRaJV_JzsLqDnF4TKUuqxkExIDdYqQYsDyqkqcb1dyTgZklHzlIulq_BSNNTH68KLBXdr5UXIChDLkOSNLArvpjr3swAA_a7pwS3ZdR1m4xyTuofkbSPMAvQ8Lt6JhTL1uuA5R4oDfGPfybhry3OcV8Qv_31cr8j97l_4muxuVrV6Q3bWVX3gQfwDtfnbpg
link.rule.ids	315,782,786,27933,27934
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+significance+of+immunohistochemical+expression+of+the+HER-2%2Fneu+oncoprotein+in+bone+metastatic+prostate+cancer&rft.jtitle=Urology+%28Ridgewood%2C+N.J.%29&rft.au=Nishio%2C+Yoshitaka&rft.au=Yamada%2C+Yoshiaki&rft.au=Kokubo%2C+Hiroto&rft.au=Nakamura%2C+Kogenta&rft.date=2006-07-01&rft.pub=Elsevier+Inc&rft.issn=0090-4295&rft.eissn=1527-9995&rft.volume=68&rft.issue=1&rft.spage=110&rft.epage=115&rft_id=info:doi/10.1016%2Fj.urology.2006.01.060&rft.externalDocID=S0090429506001300
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-4295&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-4295&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-4295&client=summon